Basic Information
| LncRNA/CircRNA Name | PVT1 |
| Synonyms | PVT1, LINC00079, MYC, NCRNA00079, onco-lncRNA-100 |
| Region | GRCh38_8:127794533-128101253 |
| Ensemble | ENSG00000249859 |
| Refseq | NR_003367 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | diffuse glioma |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | breast and ovarian cancer cell lines, glioma tumor tissue. |
| Expression Pattern | up-regulated |
| Function Description | These results implied that these four lncRNAs might play important role in diffuse gliomas progression, particularly, PVT1 and HAR1A could be explored as promising biomarkers for diagnosis, prognosis and target therapy of diffuse gliomas.Kaplan-Meier survival curve and Cox regression analyses showed that glioma patients with high PVT1 expression or low HAR1A expression had poor survival outcome, aberrantly expressed PVT1 and HAR1A could be the independent prognosis biomarkers for glioma patients. LncRNA CYTOR was up-regulated in HCC tissues, circulating CYTOR were also highly expressed in plasma samples of HCC patients, and could serve as potential biomarker for diagnosis of HHC. High expression of PVT1 and CYTOR as well as low HAR1A and MIAT expression were associated with high Ki-67 level and more TP53 mutation. |
| Pubmed ID | 29108264 |
| Year | 2017 |
| Title | lncRNAs PVT1 and HAR1A are prognosis biomarkers and indicate therapy outcome for diffuse glioma patients |
External Links
| Links for PVT1 | GenBank HGNC NONCODE |
| Links for diffuse glioma | OMIM COSMIC |